Tag: Hatch-Waxman Act
Tentative Approval vs. Final Market Entry: Navigating Patent Litigation and FDA Timelines
- Jul, 30 2026
Understand the critical gap between FDA tentative approval and final market entry for generic drugs. Learn how to navigate patent litigation, manage ANDA amendments, and avoid costly delays in the US pharmaceutical market.
- Read More
Brand companies launch authorized generics not to help patients, but to protect revenue when patents expire. These are identical drugs sold under a generic label, cutting prices while keeping market share - a strategic move that lowers costs for consumers and reshapes generic competition.